HS-14-499 Phase III  
 
An Open -Label Multicenter Study Assessing the Long -Term Safety 
of a Once- Weekly and Once -Monthly, Long -Acting Subcutaneous 
Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients 
with Opioid Use Disorder  
 
Statistical Analysis P lan (SAP) 
 
 
Sponsor  
BRAEBURN PHARMACEUTICALS 47 Hulfish Street, Suite 441  
Princeton, NJ 08542  
Tel: ( 609) 751-5375 
Fax: ( 609) 921-2156 
  
Version 1.01 
 20 April  2017 
 
 
 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   2	
  of	
  20	
   	
  SPONSOR APPROVAL  
 
The undersigned have reviewed the format and content of this prospe ctive statistical analysis plan (SAP) 
and have approved it for use to analyze the HS -14-499 data. 
  
BRAEBURN PHARMACEUTICALS  
 
 
 
Sonnie Kim, Pharm. D.   
   
 
20 Apr  2017 
     
Print Name   Signature   Date  
 
 
 
STATISTICIAN  
 
Michael Chen, Ph.D.   
  20 Apr  2017  
     
Print Name   Signature   Date  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   3	
  of	
  20	
   	
  TABLE OF CONTENTS  
1.0	
   DOCUMENT	
  HISTORY 	
  ................................ ................................ ................................ ........................... 	
  5	
  
2.0	
   LIST	
  OF	
  ABBREVIATION S	
  ................................ ................................ ................................ .................... 	
  5	
  
3.0	
   INTRODUCTION 	
  ................................ ................................ ................................ ................................ ......	
  6	
  
4.0	
   STUDY	
  DESCRIPTION 	
  ................................ ................................ ................................ ............................ 	
  6	
  
4.1	
   Study	
  Objectives 	
  ................................ ................................ ................................ ...................... 	
  6	
  
4.2	
   Study	
  Treatments 	
  ................................ ................................ ................................ .................... 	
  6	
  
4.3	
   Study	
  Design 	
  ................................ ................................ ................................ .............................. 	
  6	
  
4.4	
   Randomization	
  and	
  Blinding	
   ................................ ................................ ............................... 	
  7	
  
5.0	
   ANALYSIS	
  POPULATIONS 	
  ................................ ................................ ................................ .................... 	
  7	
  
5.1	
   Overall	
  Safety	
  Population 	
  ................................ ................................ ................................ .....	
  7	
  
5.2	
   Full	
  Exposure	
   Safety	
  Population 	
  ................................ ................................ ........................ 	
  7	
  
5.3	
   Efficacy	
  Population 	
  ................................ ................................ ................................ ................. 	
  7	
  
6.0	
   GENERAL	
  CONVENTIONS 	
  ................................ ................................ ................................ ..................... 	
  7	
  
6.1	
   Definition	
  of	
  Baseline 	
  ................................ ................................ ................................ .............	
   8	
  
6.2	
   Software 	
  ................................ ................................ ................................ ................................ ......	
  8	
  
6.3	
   Changes	
  to	
  Planned	
  Analyses 	
  ................................ ................................ .............................. 	
  8	
  
7.0	
   SAMPLE	
  SIZE 	
  ................................ ................................ ................................ ................................ ............	
   8	
  
8.0	
   DESCRIPTION	
  OF	
  THE	
  S TUDY	
  POPULATIONS 	
  ................................ ................................ ..............	
   8	
  
8.1	
   Disposition 	
  ................................ ................................ ................................ ................................ .	
  8	
  
8.2	
   Demographic	
  and	
  Baseline	
  Characteristics 	
  ................................ ................................ ....	
  8	
  
8.3	
   Medical	
  History 	
  ................................ ................................ ................................ ........................ 	
  9	
  
9.0	
   PRIOR	
  AND	
   CONCOMIT ANT	
   MEDICATIONS 	
  ................................ ................................ .................. 	
  9	
  
10.0	
   EFFICACY	
  ANALYSES 	
  ................................ ................................ ................................ ............................. 	
  9	
  
10.1.1	
   Efficacy	
  Variables 	
  ................................ ................................ ................................ ....................... 	
  9	
  
10.1.2	
   Urine	
  Toxicology	
  Results 	
  for	
  Illicit	
  Opioids 	
  ................................ ................................ .	
  10	
  
10.1.3	
   Self-­‐‑reported	
  Illicit	
  Opioid	
  Use 	
  ................................ ................................ ......................... 	
  10	
  
10.1.4	
   Retention	
  in	
  Tre atment 	
  ................................ ................................ ................................ ........	
  10	
  
10.1.5	
   Retention	
  in	
   Study	
   ................................ ................................ ................................ .................. 	
  10	
  
10.1.6	
   Measures	
  of	
  Opioid	
  Withdrawal 	
  ................................ ................................ ....................... 	
  10	
  
10.1.7	
   Measures	
  of	
  Opioid	
  Craving 	
  ................................ ................................ ............................... 	
  11	
  
10.1.8	
   Urine	
  Toxicology	
  Results 	
  for	
  Other	
  Drugs	
  of	
  Abuse 	
  ................................ ................ 	
  11	
  
10.1.9	
   Work	
  Prod uctivity	
  and	
  Activity	
  Impairment	
  Questionnaire	
  General	
  Health	
  
(WPAI -­‐‑GH)	
  ................................ ................................ ................................ ................................ .	
  11	
  
10.1.10	
   EQ-­‐‑5D-­‐‑5L	
  Health	
  Questionnaire	
   ................................ ................................ ....................... 	
  11	
  
10.1.11	
   Patient	
  Satisfaction	
  Scale 	
  ................................ ................................ ................................ .....	
  11	
  
11.0	
   SUMMARIES	
  OF	
  MEASURES	
  OF	
  SAFETY	
   ................................ ................................ ........................ 	
  11	
  
11.1.1	
   Extent	
  of	
  Exposure 	
  ................................ ................................ ................................ ................. 	
  11	
  
11.1.2	
   Adverse	
  Events 	
  ................................ ................................ ................................ ........................ 	
  12	
  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   4	
  of	
  20	
   	
  11.1.3	
   Laboratory	
  Assessments 	
  ................................ ................................ ................................ .....	
  12	
  
11.1.4	
   Vital	
  Signs 	
  ................................ ................................ ................................ ................................ ...	
  13	
  
11.1.5	
   Physical	
  Exam ination 	
  ................................ ................................ ................................ ............	
   13	
  
11.1.6	
   12-­‐‑Lead	
  Electrocardiogram 	
  ................................ ................................ ............................... 	
  13	
  
11.1.7	
   Injecti on	
  Site	
  Examination	
   ................................ ................................ ................................ ..	
  13	
  
11.1.8	
   C-­‐‑SSRS	
   ................................ ................................ ................................ ................................ ..........	
   13	
  
12.0	
   IDENTIFICATION	
  AND	
  S UMMARY	
  OF	
  PROTOCOL	
  D EVIATIONS 	
  ................................ ...........	
   13	
  
13.0	
   DATA	
  QUALITY	
  ASSURAN CE	
  ................................ ................................ ................................ ............	
   14	
  
14.0	
   REFERENCES 	
  ................................ ................................ ................................ ................................ ..........	
   14	
  
15.0	
   APPENDICES 	
  ................................ ................................ ................................ ................................ ..........	
   14	
  
15.1	
   Appendix	
  A	
   -­‐‑	
  List	
  of	
  Tables,	
  Listings,	
  and	
  Figures 	
  ................................ ...................... 	
  14	
  
15.2	
   Appendix	
  B	
   -­‐‑	
  Imputation	
  Algorithm	
  for	
  Partial	
  and	
  Missing	
  Dates 	
  ...................... 	
  20	
  
 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   5	
  of	
  20	
   	
  1.0   DOCUMENT	
  HISTORY 	
  
Version  Date  Changes made since previous version  
1.00 25 January 2017 Final   
 
1.01 20 April 2017 Updates on the sample size  and inclusion of separate analysis of 
subjects new to treatment.  
 
2.0   LIST	
  OF	
  ABBREVIATION S	
  
Abbreviatio n Definition  
AE Adverse Event 
BPN  Buprenorphine or Buprenorphine/Naloxone  
COWS  Clinical Opiate  Withdrawal Scale  
CRF  Case Report Form (may include electronic data capture systems or paper forms)  
C-SSRS Columbia -Suicide Severity Rating Scale  
ECG  Electr ocardiogram  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
PT MedDRA Preferred Term  
SAE  Serious Adverse Event 
SAP Statistical Analysis Plan 
SC Subcutaneous  
SD Standard Deviation  
SL Sublingual  
SOC  MedDRA System Organ Class  
SOWS Subjective Opiate  Withdrawal Scale  
TEAE Treatment -Emergent Adverse Event 
VAS  Visual Analog ue Scale  
WPAI -GH Work Productivity and Activity Impairment Questionnaire General Health  
 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   6	
  of	
  20	
   	
  3.0   INTRODUCTION 	
  
This statistical analysis plan (SAP) is based on Protocol HS-14-499, Version  3.0, dated 18-Nov-2016.  
The purpose of this document is to provide details on study populations and on how the variables will be 
derived, how missing data will be handled, as well as details on statistical method ologie s to be used to 
analyze the safety and efficacy data from the study.   
 
The document may evolve over time, for example, to reflect the requirements of protocol amendments  or 
regulatory requests. However, the final SAP must be finalized, approved  by the Sponsor , and placed on 
file before the database is locked and treatment codes are unblinded . Deviations from the approved plan 
will be noted in the clinical study report.  
4.0   STUDY	
   DESCRIPTION 	
  
4.1   STUDY	
  OBJECTIVES 	
  
Primary Objective:  To demonstrate the safety and tolerability of C AM2038 products in 12 -month 
(48-week) buprenorphine (BPN) treatment in adult outpatients with opioid use disorder.  
 Secondary Objectives:  To evaluate efficacy of CAM2038 through several efficacy parameters, including 
urine toxicology, signs and symptoms of withdr awal and cravings in adult outpatients with opioid use 
disorder.   
4.2   STUDY	
  TREATMENT S	
  	
  
Following Screening, qualified patient s will be initiated on either CAM2038 q1w or q4w, based on their 
current treatment status (qualified patient s currently on sublingual (SL) BPN or seeking BPN treatment).  
Qualified patient s will be initiated or transitioned to CAM2038 q1w or q4w as follows:  
 
•  Initiation of BPN treatment – initiate with CAM2038 q1w  
•  Currently receiving SL BPN treatments – transfer to corresponding CAM2038 q1w or q4w dose 
 
Patient s will be allowed to receive supplemental BPN during the study with booster SC injections of 
CAM2038 q1w 8 mg up to a maximum dose of 40  mg CAM2038q1w per week . For patients on 
CAM2038  q4w, a maximum of two booster doses of CAM2038 q1w 8 mg SC injection s may be given 
per week. Dose adjustments (up or down titrations) will also be allowed at scheduled visits.  
4.3   STUDY	
  DESIGN	
  
This is an open -label multi -center, 12 -month safety study, consistent with standard practice for long -term 
safety studies. This one -year safety study will utilize CAM2038 q1w (once weekly) and CAM2038 q4w 
(once monthly) and will have 3 phases: Screening, Treatment, and Follow -up.   
 
Patients who are currently taking SL BPN (weekly or monthly prescription visits) or i ndividuals who are 
actively seeking BPN treatment but who have not yet begun a treatment regimen, may be el igible for the 
study.  
 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   7	
  of	
  20	
   	
  Following Screening, qualified patient s will be initiated on either CAM2038 q1w or CAM2038 q4w and 
receive study treatment  as described in Section  4.3.  
 
The study will end when at least 100 patient s have been exposed to CAM2038 for 12 months (48 weeks). 
All patient s will be transitioned back to usual care and followed for an  additional 4 weeks (up t o 
Week  53).  
4.4   RANDOMIZATION	
  AND	
  BL INDING 	
  
This is an open -label study.   
5.0   ANALYSIS	
  POPULATIONS 	
  
5.1   OVERALL	
  SAFETY	
  POPULATION	
  
All patient s who received at least one dose of CAM2038 . 
5.2   FULL	
  EXPOSURE	
  SAFETY 	
  POPULATION 	
  
All patient s who have been exposed to CAM2038 for 4 8 weeks . 
5.3   EFFICACY 	
  POPULATION 	
  
In addition to the protocol -specified populations, t he efficacy  population will include all patient s who 
have received at least one dose  of CAM2038  and have provided some post- baseline efficacy 
measurements .   
6.0   GENERAL	
  CONVENTIO NS	
  
Unless otherwise stated, all analyses will be performed using SAS Version 9 and all hypothesis tests will be conducted at a two -sided significance level of 0.05.  P-values will be presented with 3 decimals and p -
values that are less than 0.001 will be pr esented as <0.001. 
 
Continuous (non-survival -related) data will be summarized using descriptive statistics: number of 
observations (n), mean, standard deviation (SD), median, minimum, and maximum. Frequencies and percentages will be used to summarize categ orical (discrete) data.  Presentations of  categorical data will 
generally suppress  percentages  for items where the  count is zero in order to draw attention to the nonzero 
counts.   In general, mean, standard deviation, median, minimum, maximum, and percenta ges will be 
presented with one decimal.  
 Unless otherwise stated, c onfidence intervals, when presented, will be constructed at the two-sided 95% 
level.  For binomial variables, the 95% confidence intervals will be constructed using the normal 
approximation  without continuity correction.  
 
Data listings will present all data collected on case report forms ( CRFs ) by study drug, center, and patient  
number.    
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   8	
  of	
  20	
   	
  6.1   DEFINITION	
  OF	
  BASELI NE	
  
Unless otherwise stated , the last observed measurement before the first dose of CAM2038 will be 
consi dered the baseline measurement.  If multiple observations are made during baseline, the baseline will 
be defined as average of the observations obtained during the baseline phase.  
6.2   SOFTWARE 	
  
Most a nalyses will be conducted using SAS Versio n 9.2 or higher .   
6.3   CHANGES	
  TO	
  PLANNED	
  A NALYSES	
  
Draft versions of the SAP will be numbe red sequentially as Version 0.0 i. The final approved version will 
be numbered as Ver sion 1.00. Revisions after the “Final” version will be numbered as Version 1.0x. The 
clinical study r eport will document any changes made after the final version approved before database 
lock. 
7.0   SAMPLE	
  SIZE 	
  
A total of 100 patient s with at least 48 weeks of CAM2038 exposure will be needed for the safety 
assessments. Approximately 228 patient s will be enrolled initially into this study with an estimated drop -
out rate of 50% to ensure a total of 100 patient s are exposed to CAM2038. Originally, the study was to 
end when at least 100 subjects had been exposed to CAM2038  for 12 months (48 weeks). Ho wever, a 
decision was made to allow all enrolled subjects to complete the entire treatment period and to not end the 
study after at least 100 subjects had completed 48 weeks of treatment.    
8.0   DESCRIPTION	
  OF	
  THE	
   STUDY	
  POPULATIONS 	
  
All tables, figures, and lis tings must include a population descriptor (e.g., pre-defined populations: overall 
safety population, full exposure safety population and efficacy population ) in the title . 
8.1   DISPOSITION 	
  
Patient  disposition  summaries will be presented and will include the nu mber  of patient s enrolled , the 
number  and percentage of enrolled  patient s in each of the pre -defined population s, as well as the number 
and percentage of patient s who complete the study .  The summaries will also include the reasons for early 
discontinuatio n from the  study.    
 Disposition summaries will be presented for each of the pre -defined populations  separately.  
8.2   DEMOGRAPHIC	
  AND	
  BASE LINE	
  CHARACTERISTICS 	
  
A summary of demographics and baseline characteristics will be presented for each of the pre -defined  
population s.  The demographic characteristics will  consist of age, sex, ethnicity,  and race using 
descriptive statistics.  
 
Demographic data including age, race, ethnicity, and gender, as well as baseline clinical characteristics 
will be summarized. Age will  be calculated based on the following conditional algorithm:  
 
•  Has the patient had his/her  birthday this year?  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   9	
  of	
  20	
   	
  o  Yes, then AGE = (year of informed consent) – (year of birth).  
o  No, then AGE = (year of informed consent) – (year of birth) – 1. 
 
Clinical baseline  characteristics summarized will include , if available,  weight, body mass index , region 
(Europe, the US and Australia) , type of primary opioid use, years of drug use, when first diagnosed with 
opioid dependence , proportion of patients previously treated fo r opioid dependence and duration of 
buprenorphine treatment .  
8.3   MEDICAL	
  HISTORY 	
  
Medical history will be coded using  the Medical Dictionary for Regulatory Activities (MedDRA ). 
Medical history  will be summarized and listing s will be present ed.   
9.0   PRIOR 	
  AND	
   CONC OMITANT 	
  MEDICATIONS 	
  
All medications recorded on the CRFs will be coded using the WHO DRUG Dictionary . Prior and 
concomitant medications will be summarized by anatomical therapeutic chemical  (ATC) Class Level 4 
and WHO Drug base substance preferred name.  
 
Prior medications are defined as medications with stop date s occurring before the date of the first 
administration of any study treatment  component . Concomitant medications are defined as medications 
with start dates occurring on or after the date of the first administration of any study treatment component  
and no more than 30 days after the last administration of any study treatment component . Medications 
with start and stop dates that bracket the date of the first administration of any study treatment comp onent 
will be summarized as both prior and concomitant medications.  
 
Medications that clearly stopped prior to date of the first administration of any study treatment component  
will be included in the prior medications table, and medications that clearly s tarted on or after date of the 
first administration of any study treatment component will be included in the concomitant medications 
table. All other medications will be included in both the prior and concomitant medications tables.  
 Prior and Concomitant medication will be summarized for the safety population s. 
10.0   EFFICACY	
  ANALYSES 	
  
10.1.1   EFFICACY	
  VARIABLES 	
  
This is a long -term safety study  and e fficacy evaluation is not the primary objective of the study . All 
efficacy variables will be summarized  using the efficacy population . The efficacy variables will include 
the following:  
•  Urine toxicology results for illicit opioids  
•  Self-reported illicit opioid use  
•  Retention (%) in treatment  (identical to exposure) 
•  Retention (%) in study  
•  Measures of opioid withdrawal:  
o  Clinic al Opiate Withdrawal Scale (COWS)  
o  Subjective Opiate Withdrawal Scale (SOWS)  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   10	
  of	
  20	
   	
  •  Measures of opioid craving:  
o  Desire to Use Visual Analogue S cale (VAS)  
o  Need to Use VAS  
•  Urine toxicology results for other drugs of abuse  
•  Work Productivity and Activity Impairment Q uestionnaire General Health (WPAI -GH) 
•  EQ-5D-5L Health Questionnaire  
•  Patient Satisfaction Scale  
10.1.2   URINE	
  TOXICOLOGY	
  RES ULTS	
   FOR	
  ILLICIT	
  OPIOIDS 	
  
Percent age of  patients with urine samples negative for illicit opioids (with and without self-reports of 
illicit opi oid use) will be presented by week  and month . Mean percentage of urine samples negative for 
illicit opioids (with and without self -reports of illicit opioid use) will also be presented. Additionally, 
mean urine samples negative for illicit opioids (with an d without self -reports) will be presented by week 
and month separately for those subjects who were new to treatment upon entry into the study.  Due to the 
flexible visit schedule, no imputation of missing data will be applied.  
10.1.3   SELF-­‐‑ REPORTED	
  ILLICIT	
  OPI OID	
  USE	
  
Percentage of patients reporting no illicit opioid use will be presented by week  and month . Mean 
percentage of reports of no illicit opioid use will also be presented. Due to the flexible visit schedule, no 
imputation of missing data will be applied.  
10.1.4   RETENTION	
  IN	
  TREATME NT	
  
Duration of treatment is defined as the time  from the first dose of CAM2038 to the last dose plus 28 days 
if the last treatment was CAM2038 q4w or plus 7 days if the last treatment was CAM2038 q1w.  
 
Duration of treatment  will be sum marized by the percentage of patients retained in treatment by week . 
Data will also be presented using Kaplan -Meier plots.  
10.1.5   RETENTION	
  IN	
   STUDY	
  
Duration in study is defined as the time from first dose of CAM2038 to the date of study discontinuation.  
 
Durat ion in study will be summarized by the percentage of patients  retained in the study by week . Data 
will also be presented using Kaplan -Meier plots.  
10.1.6   MEASURES	
  OF	
  OPIOID	
  W ITHDRAWAL	
  
Measures  of withdrawal  include  COWS  and SOWS.  The COWS  is comprised  of 11 items, each with a 
score of 0 through  4 or 5.  Higher  scores  are associated  with greater  withdrawal  symptoms.  The items  are 
meant  to be objective  measures  of a patient’s  withdrawal  symptoms  (e.g.,  resting  pulse  rate). The SOWS 
is comprised  of 16 items  each with a score of 0 through  4. Higher  scores  are associated  with greater  
withdrawal  symptoms.  The items  are statements  that are evaluated  by the patient  and are therefor e 
subjective  (e.g.,  I feel anxious,  0 = not at all, 1 = a little, 2 = moderately,  3 = quite  a bit, 4 = extremely).   
 If there  are >=3 (i.e., >=20%)  missing  items  in the COWS  scale  at a given  visit or >=4 (i.e., >20%)  
missing  items  in the SOWS scale at a given  visit,  the COWS/SOWS  score for that visit will be missing.  If 
there  are 1 or 2 missing  items  for the COWS  assessment  then the total of the non-missing  items  will be 
calculated  and the product  of the calculated  total and 11/(11 - # missing)  will be used for the COWS  score 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   11	
  of	
  20	
   	
  for that visit.  If 3 or fewer items  are missing  for the SOWS score then the total of the non-missing  items  
will be calculated  and the product  of the calculated  total and 16/(16  - # missing)  will be used for the 
SOWS score.  
 
COWS and SOWS data will be presented by visit. Data will also be presented  as change from baseline by 
subtracting the baseline values from the post -baseline values. Negative changes are thus indicative of 
improvement.  
10.1.7   MEASURES	
  OF	
  OPIOID	
   CRAVING	
  
Measures  of craving  include  Desire  to Use VAS  and Need  to Use VAS and  will be assessed  using 
unipolar  100 mm VAS ; “Since your last scheduled assessment visit, indicate your worst or strongest 
desire/need to use opioids between 0 = No desire /need  to use and 100 = Maximum  desire /need to use on 
this scale” .  
 
VAS data for Desire to Use and Need to Use will be presented  by visit.  Data will also be presented as 
change from baseline by subtracting the baseline values from the post -baseline values. Negative changes 
are thus indicative of improvement. 
10.1.8   URINE	
  TOXICOLOGY	
  RES ULTS	
   FOR	
  OTHER	
  DRUGS	
  OF	
  A BUSE 	
  
Percentage of patients with  urine samples positive for other drugs of abuse will be presented by week and 
month. Mean percentage of urine samples positive for other drugs of abuse will also be presented. Due to 
the flexible visit schedule, no imputation of missing data will be appli ed.  
10.1.9   WORK	
  P RODUCTIVITY	
  AND	
  ACTI VITY	
  IMPAIRMENT	
  QUES TIONNAIRE	
  
GENERAL	
  HEALTH	
  (WPAI -­‐‑GH)	
  
Data	
  for	
  WPAI -­‐‑GH	
  will	
  be	
  presented	
  by	
  item	
  over	
  time.	
   	
  
10.1.10    EQ-­‐‑5D-­‐‑5L	
  HEALTH	
  QUESTIONNA IRE	
  
Data for EQ -5D-5L will be presented over time.  
10.1.11    PATIENT	
  SATISFACTION 	
  SCALE 	
  
Patient sa tisfaction scale scores will be presented by item over time.  
11.0   SUMMARIES 	
  OF	
  MEASURES	
  OF	
  SAFET Y	
  
Safety analyses will be performed for the overall safety population  and full exposure safety population .   
 
Safety evaluations will be based on the incidence, int ensity and type of adverse events  (AEs), as well as 
on clinically significant changes in the patient ’s vital signs, electrocardiogram ( ECG ), clinical laboratory 
results  and injection  site examination s. 
11.1.1   EXTENT	
  OF	
  EXPOSURE	
  
Summary statistics (number and perc entage) of weeks of exposure to study drug (i.e. from the date of  the 
first injection  to the date of the last injection  plus 28 days if the last treatment was CAM2038 q4w or plus 
7 days if the last treatment was CAM2038 q1w) will be presented . Number of pa tients, number of 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   12	
  of	
  20	
   	
  injections and exposure years will be presented by dose, treatment (CAM2038 q1w and CAM2038 q4w)  
and in total .  
11.1.2   ADVERSE	
  EVENTS 	
  
Each AE and serious adverse event ( SAE ) term recorded on the CRFs by primary system organ class 
(SOC) and will be mapped to a preferred term (PT) using the MedDRA dictionary. T he Investigator will 
assess AE  severity and relationship to the study treatment.  
 
A treatment -emergent adverse event (TEAE) is defined as any AE with an onset date on or after the date 
of the first study treatment , or any ongoing event started on the date of the first dose that worsens in 
severity. Only AEs with an onset date prior to the date of the last dose + 30 days will be tabulated in 
summary tables.  For the purpose of calculating treatm ent emergence and inclusion in summary tables, 
incomplete onset dates will be imputed as detailed in Appendix B.   
 
AEs will be summarized by the number and percent of patients in each primary SOC and PT. Patients will 
be counted only once for each primary  SOC and each PT. Summary tables of AEs by primary SOC, PT 
and intensity will be provided. If a patient has more than one AE coded to the same PT, the patient will be 
counted only once for that PT by using the event with the highest intensity. Similarly, i f a patient has 
more than one AE within a primary SOC category, the patient will be counted only once in that SOC 
category by using the event with the highest intensity. AEs by primary SOC, PT and relationship to study 
drug will be provided as well. If a p atient has more than one AE coded to the same PT, the patient will be 
counted only once for that PT by using the most related event. Similarly, if a patient has more than one 
AE within a primary SOC category, the patient will be counted only once in that p rimary SOC category 
by using the most related event. In addition, SAE s by primary SOC and PT will be provided. Deaths and 
SAEs will be summarized similarly to AEs. All AE tables will also include the total number of events, 
counting multiple events per patient.  
Injection -related AEs, other (non -injection  related) AEs as well as all AEs will be presented. Summaries 
of these AE subsets will be presented for the following categories:  
•  Study drug -related  
•  Intensity  
•  Serious  
•  AEs which led to treatment /study  discon tinuation  
•  SAEs which led to treatment /study  discontinuation  
•  AEs occurring in 5% or greater of patients (by preferred term) 
 
In the AE summary, the SOCs and the PTs within each SOC will appear in descending order of 
frequency .   
 Frequencies of deaths and hospitalizations will also be summarized.  
Other safety analyses will be performed as appropriate  
11.1.3   LABORATORY	
  ASSESSMEN TS	
  
Chemistry, hematology, urinalysis and coagulation profile will be assessed at baseline and over time .  
Summary statistics for these param eters will be presented by visit for the actual value and change from 
baseline for each test in each laboratory category ( hematology, chemistry, urinalysis, and coagulation 
profile). Shift tables will be presented for shifts from baseline lab  categories  to end of study laboratory 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   13	
  of	
  20	
   	
  category.  The three laboratory categories will be:  L ( below lower bound of normal range ), N (within 
normal range) , and H (above high er bound of normal range) .    
If a lab value is reported using a non -numeric qualifier (e.g., les s than (<) a certain value, or greater than 
(>) a certain value), the given numeric value will be used in the summary statistics, ignoring the non -
numeric qualifier.  
If a patient has repeated laboratory values for a given time point, the value from the fir st evaluation at that 
time point will be used for summarization purposes. For the purpose of determining baseline, the last non -
missing observation on or prior to  first dose of CAM2038 .   
11.1.4   VITAL	
  SIGNS	
  
Vital signs will be assessed over time . Vital sign  value s and change from baseline in the vital signs will 
be summarized.  
11.1.5   PHYSICAL	
  EXAM INATION 	
  
Physical examination  data at Screening will be summarized . 
11.1.6   12-­‐‑LEAD	
  ELECTROCARDIOGR AM	
  
12-Lead ECGs will be assessed over time . The ECG variables will include ventricular heart rate and the 
PR, QRS, QT, QTcB and QTcF intervals. The ECGs will be signed and dated by a medically -qualified 
individual to confirm review of the ECG and verify whether any abnormalities are clinically significant.  
 
Number and percent of patients in  each ECG finding category (normal, abnormal not clinically 
significant, and abnormal and clinically significant), wi ll be summarized for each visit . Summary 
statistics will be presented for the actual value and change for each ECG parameter.  
 
The number a nd percent of patient s with QT, QTcB and QTcF intervals < 450 msec, 450 to <480, 480 to 
<500 and greater than/equal to 500 msec at each visit and overall (at any visit) will be summarized. Additionally, the number and percentage of patient s with increases  in these parameters of <30 msec, 30 to 
<60 msec and greater than/equal to 60 msec will be summarized at each visit.  
11.1.7   INJECTION 	
  SITE	
  EXAMINATION	
  
The injection  site will be visually inspected for evidence of erythema, edema, itching, pain, infection, 
bleedin g, abnormal healing and any other abnormalities .   
 
AEs that are believed to be associated with injection  procedures will be summarized similarly to the 
summaries for other AEs (not associated with injection  procedures).  
11.1.8   C-­‐‑SSRS	
  
Data on Columbia -Suicide Sev erity Rating Scale (C -SSRS)  will be summarized over time.  
12.0   IDENTIFICATION	
  AND	
  SUMMARY	
  OF	
  PROTOCOL	
  D EVIATIONS 	
  
Major protocol deviations from entry criteria and treatment compliance will be summarized as far as they 
can be extracted from numeric or coded stu dy data.  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   14	
  of	
  20	
   	
  13.0   DATA	
  QUALITY	
  ASSURAN CE	
  
Accurate and reliable data collection will be ensured by verification and cross check of the CRFs against 
the investigator’s records by the study monitor (source document verification) and by the maintenance of 
a drug –dispen sing log by the investigator.  Collected data will be entered into a computer database and 
subject  to electronic and manual quality assurance procedures.  
14.0   REFERENCES 	
  
Not	
  applicable. 	
  
15.0   APPENDICES	
  
15.1   APPENDIX	
  A	
  -­‐‑ 	
  LIST	
  OF	
  TABLES,	
  LIST INGS,	
  AND	
  FIGURES	
  	
  
List of Tabl es 
Number  Title  
TABLE 14.1.1.1 Disposition of Enroll ed Patients (Overall Safety Population)  
TABLE 14.1.1.2 Disposition of Enroll ed Patients (Full Exposure Safety Population)  
TABLE 14.1.1.3 Disposition of Enroll ed Patients ( Efficacy  Population)  
TABLE 14 .1.2.1 Demographics ( Overall Safety Population)  
TABLE 14.1.2.2  Demographics ( Full Exposure Safety Population)  
TABLE 14.1.2.3  Demographics ( Efficacy  Population)  
TABLE 14.1.3.1  Baseline Clinical Characteristics ( Overall Safety Population)  
TABLE 14.1.3.2  Baseline Clinical Characteristics ( Full Exposure Safety Population)  
TABLE 14.1.3.3  Baseline Clinical Characteristics ( Efficacy  Population)  
TABLE 14.1.4.1  Summary of Psychiatric History ( Overall Safety Population)  
TABLE 14.1.4.2  Summary of Psychiatric Hi story ( Full Exposure Safety Population)  
TABLE 14.1.4.3  Summary of Psychiatric History ( Efficacy  Population)  
TABLE 14.1.5.1.1  Prior Medications ( Overall Safety Population)  
TABLE 14.1.5.1.2  Prior Medications ( Full Exposure Safety Population)  
TABLE 14.1.5.1 .3 Prior Medications ( Efficacy  Population)  
TABLE 14.1.5.2.1  Concomitant Medications ( Overall Safety Population)  
TABLE 14.1.5.2.2  Concomitant Medications ( Full Exposure Safety Population)  
TABLE 14.1.5.2.3  Concomitant Medications ( Efficacy  Population)  
TABLE 14.1.6.1  Substance Abuse Treatment History ( Overall Safety Population)  
TABLE 14.1.6.2  Substance Abuse Treatment History ( Full Exposure Safety Population)  
TABLE 14.1.6.3  Substance  Abuse Treatment History ( Efficacy  Population)  
TABLE 14.2.1.1  Summary  of Urine Toxicology Results for Illicit O pioid  Use Supported by Self -
Reported Illicit Opioid U se over Time (Efficacy  Population)  
TABLE 14.2.1.2 Summary of Urine Toxicology Results for Illicit Opioid  Use Without Self -
Reported Illicit Opioid U se over Time (Efficacy  Population)  
TABLE 14.2.2.1 Summary of Mean Percentage of Urine Toxicology Results for Illicit O pioid  Use 
Supported by Self -Reported Illicit Opioid U se (Efficacy  Population)  
TABLE 14.2.2.2 Summary of Mean Percentage of Urine Toxicology Results f or Illicit O pioid  Use 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   15	
  of	
  20	
   	
  Without Self -Reported Illicit Opioid U se (Efficacy  Population)  
TABLE 14.2.2.3 Summary of Mean Percentage of Urine Toxicology Results for Illicit Opiiods 
Use Supported by Self -Reported Illicit Opioid Use by Treatmentment Status at 
Baseline (New to Treatment [Yes/No])  
TABLE 14.2.2.4 Summary of Mean Percentage of Urine Toxicology Results for Illicit O pioid  Use 
Without Self -Reported Illicit Opioid U se by Treatment Status at Baseline (New 
to Treatment [Yes/No]) ( Efficacy  Population)  
TABLE 14.2.3.1 Summary of Self -Reported Illicit Opioid U se over Time  (Efficacy  Population)  
TABLE 14.2.3.2 Summary of Mean Percentage of Self-Reported Illicit Opioid U se (Efficacy  
Population)  
TABLE 14.2.4.1 Summary of Retention (%) in T reatment  over Time ( Efficacy  Population)  
TABLE 14.2.4.2 Time to End of Retention in T reatment  (Efficacy  Population)  
TABLE 14.2.5.1 Summary of Retention (%) in Study over Time ( Efficacy  Population)  
TABLE 14.2.5.2 Time to End of Retention in Study ( Efficacy  Population)  
TABLE 1 4.2.4.3  Summary of Retention (%) in T reatment  over Time by Treatment Status at 
Baseline (New to Treatment [Yes/No]) ( Efficacy  Population)  
TABLE 14.2.4.4 Time to End of Retention in T reatment  by Treatment Status at Baseline (New to 
Treatment [Yes/No]) ( Efficacy  Population)  
TABLE 14.2.6 Summary of Clinical Opiate Withdrawal Scale (COWS) over Time ( Efficacy  
Population)  
TABLE 14.2.7 Summary of Subjective Opiate  Withdrawal Scale  (SOWS) over Time ( Efficacy  
Population)  
TABLE 14.2.8 Summary of Desire to Use VAS  over Time ( Efficacy  Population)  
TABLE 14.2.9 Summary of Need to Use VAS  over Time ( Efficacy  Population)  
TABLE 14.2.10.1 Summary of Urine Toxicology Results for Other Drugs of Abuse over Time 
(Efficacy  Population)  
TABLE 14.2.10.2 Summary of Mean Percent age of Urine Toxicology Results for Other Drugs of 
Abuse (Efficacy  Population)  
TABLE 14.2.11 Summary of Work Productivity and Activity Impairment Questionnaire General 
Health (WPAI -GH) by Item over Time (Efficacy Population)  
TABLE 14.2.12 Summary of EQ -5D-5L Health Questionnaire Data over Time (Efficacy 
Population)  
TABLE 14.2.13 Summary of Patient Satisfaction Scale Scores by Item over Time (Efficacy 
Population)  
TABLE 14.3 .1.1 Summary of CAM2038 Exposure  over Time  (Overall Safety Population) 
TABLE 14.3 .1.2 Summary of CAM2038 Exposure  over Time  (Full Exposure Safety Population)  
TABLE 14.3.1.3 Summary of CAM2038 Exposure by Dose and Number of Injections (Overall 
Safety Population)  
TABLE 14.3.1.4 Summary of CAM2038 Exposure by Dose and Number of Injectio ns (Full 
Exposure Safety Population)  
TABLE 14.3 .2.1 Summary of All Adverse Events by System Organ Class, Preferred Term, and 
Relationship ( Overall Safety Population)  
TABLE 14.3 .2.2 Summary of All Adverse Events by System Organ Class, Preferred Term, and 
Relationship ( Full Exposure Safety Population)  
TABLE 14.3 .2.3 Summary of All Injection -Related Adverse Events by System Organ Class, 
Preferred Term, and Relationship ( Overall Safety Population)  
TABLE 14.3 .2.4 Summary of All Injection -Related Adverse Even ts by System Organ Class, 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   16	
  of	
  20	
   	
  Preferred Term, and Relationship ( Full Exposure Safety Population)  
TABLE 14.3.2.5 Summary of All Injection -Related Adverse Events by Preferred Term, Time to 
Onset and Duration (Overall Safety Population)  
TABLE 14.3.2.6 Summary o f All Injection -Related Adverse Events by Preferred Term, Time to 
Onset and Duration (Full Exposure Safety Population)  
TABLE 14.3 .2.7 Summary of All Non-Injection Related Adverse Events by System Organ Class, 
Preferred Term, and Relationship ( Overall Safety Population)  
TABLE 14.3 .2.8 Summary of All Non-Injection Related Adverse Events by System Organ Class, 
Preferred Term, and Relationship ( Full Exposure Safety Population)  
TABLE 14.3.3.1 Summary of All Suspected to Be Drug -Related Adverse Events by Syste m Organ 
Class and Preferred Term ( Overall Safety Population)  
TABLE 14.3.3.2 Summary of All Suspected to Be Drug -Related Adverse Events by System Organ 
Class and Preferred Term ( Full Exposure Safety Population)  
TABLE 14.3.3.3 Summary of All Injection Rela ted Suspected to Be Drug -Related Adverse Events 
by System Organ Class and Preferred Term ( Overall Safety Population)  
TABLE 14.3.3.4 Summary of All Injection Suspected to Be Drug -Related Adverse Events by 
System Organ Class and Preferred Term ( Full Exposur e Safety Population)  
TABLE 14.3.3.5 Summary of All Non-Injection Related Suspected to Be Drug -Related Adverse 
Events by System Organ Class and Preferred Term ( Overall Safety Population)  
TABLE 14.3.3.6 Summary of All Non-Injection Suspected to Be Drug -Related Adverse Events by 
System Organ Class and Preferred Term ( Full Exposure Safety Population)  
TABLE 14.3.4.1 Summary of All Adverse Events by System Organ Class , Preferred Term,  and 
Severity (Overall Safety Population)  
TABLE 14.3.4.2 Summary of All Adve rse Events by System Organ Class , Preferred Term,  and 
Severity (Full Exposure Safety Population)  
TABLE 14.3.4.3 Summary of All Injection -Related Adverse Events by System Organ Class , 
Preferred Term,  and Severity  (Overall Safety Population)  
TABLE 14.3.4.4 Summary of All Injection -Related Adverse Events by System Organ Class , 
Preferred Term,  and Severity  (Full Exposure Safety Population)  
TABLE 14.3.4.5 Summary of All Non-Injection Related Adverse Events by System Organ Class , 
Preferred Term,  and Severity  (Overall Safety Population)   
TABLE 14.3.4.6 Summary of All Non-Injection Related Adverse Events by System Organ Class , 
Preferred Term,  and Severity  (Full Exposure Safety Population)  
TABLE 14.3. 5.1.1  Summary of Most Common (at least 5%) Adverse Events by S ystem Organ 
Class and Preferred Term ( Overall Safety Population)  
TABLE 14.3. 5.1.2  Summary (number of patient s and number of events) of Most Common (at least 
5%) Non-Serious Adverse Events by System Organ Class and Preferred Term 
(Overall Safety Population ) 
TABLE 14.3. 5.1.3  Summary (number of patient s and number of events) of Serious Adverse Events 
by System Organ Class and Preferred Term ( Overall Safety Population)  
TABLE 14.3. 5.2 Summary of Most Common (at least 5%) Adverse Events by System Organ 
Class a nd Preferred Term ( Full Exposure Safety Population)  
TABLE 14.3. 5.3 Summary of Most Common (at least 5%) Injection -Related Adverse Events by 
System Organ Class and Preferred Term ( Overall Safety Population)  
TABLE 14.3. 5.4 Summary of Most Common Injection -Related (at least 5%) Adverse Events by 
System Organ Class and Preferred Term ( Full Exposure Safety Population)  
TABLE 14.3. 5.5 Summary of Most Common (at least 5%) Non-Injection Related Adverse Events 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   17	
  of	
  20	
   	
  by System Organ Class and Preferred Term ( Overall Safety Population)  
TABLE 14.3. 5.6 Summary of Most Common Non-Injection Related (at least 5%) Adverse Events 
by System Organ Class and Preferred Term ( Full Exposure Safety Population)  
TABLE 14.3. 6.1 Summary of All Serious Adverse Events by System Organ Class and Preferred 
Term ( Overall Safety Population)  
TABLE 14.3. 6.2 Summary of All Serious Adverse Events by System Organ Class and Preferred 
Term ( Full Exposure Safety Population)  
TABLE 14.3. 6.3 Summary of All Injection -Related Serious Adverse Events by Syste m Organ 
Class and Preferred Term ( Overall Safety Population)  
TABLE 14.3. 6.4 Summary of All Injection -Related Serious Adverse Events by System Organ 
Class and Preferred Term ( Full Exposure Safety Population)  
TABLE 14.3. 6.5 Summary of All Non-Injection Rel ated Serious Adverse Events by System 
Organ Class and Preferred Term ( Overall Safety Population)  
TABLE 14.3. 6.6 Summary of All Non-Injection Related Serious Adverse Events by System 
Organ Class and Preferred Term ( Full Exposure Safety Population)  
TABLE 1 4.3.7.1 Summary of All Adverse Events That Lead to Treatment/ Study Discontinuation 
by System Organ Class and Preferred Term ( Overall Safety Population)  
TABLE 14.3. 7.2 Summary of All Adverse Events That Lead to Treatment/ Study Discontinuation 
by System Organ Class and Preferred Term ( Full Exposure Safety Population)  
TABLE 14.3. 7.3 Summary of All Injection Related Adverse Events That Lead to Treatment/ Study 
Discontinuation by System Organ Class and Preferred Term ( Overall Safety 
Population)  
TABLE 14.3. 7.4 Summary of All Injection -Related Adverse Events That Lead to Treatment/ Study 
Discontinuation by System Organ Class and Preferred Term ( Full Exposure 
Safety Population)  
TABLE 14.3. 7.5 Summary of All Non-Injection Related Adverse Events That Lead to 
Treatme nt/Study Discontinuation by System Organ Class and Preferred Term 
(Overall Safety Population)  
TABLE 14.3. 7.6 Summary of All Non-Injection Related Adverse Events That Lead to 
Treatment/ Study Discontinuation by System Organ Class and Preferred Term 
(Full Ex posure Safety Population)  
TABLE 14.3. 8.1 Summary of All Serious Adverse Events That Lead to Treatment/ Study 
Discontinuation by System Organ Class and Preferred Term ( Overall Safety 
Population)  
TABLE 14.3. 8.2 Summary of All Serious Adverse Events That Lea d to Treatment/ Study 
Discontinuation by System Organ Class and Preferred Term ( Full Exposure 
Safety Population)  
TABLE 14.3. 8.3 Summary of All Injection Related Serious Adverse Events That Lead to 
Treatment/ Study Discontinuation by System Organ Class and P referred Term 
(Overall Safety Population)  
TABLE 14.3. 8.4 Summary of All Injection Related Serious Adverse Events That Lead to 
Treatment/ Study Discontinuation by System Organ Class and Preferred Term 
(Full Exposure Safety Population)  
TABLE 14.3. 8.5 Summar y of All Non-Injection Related Serious Adverse Events That Lead to 
Treatment/ Study Discontinuation by System Organ Class and Preferred Term 
(Overall Safety Population)  
TABLE 14.3. 8.6 Summary of All Non-Injection Related Serious Adverse Events That Lead to  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   18	
  of	
  20	
   	
  Treatment/ Study Discontinuation by System Organ Class and Preferred Term 
(Full Exposure Safety Population)  
TABLE 14.3. 9.1 Summary of All Deaths and Hospitalizations ( Overall Safety Population)  
TABLE 14.3. 9.2 Summary of All Deaths and Hospitalizations ( Full Exposure Safety Population)  
TABLE 14.3. 9.3 Summary of All Injection -Related Deaths and Hospitalizations ( Overall Safety 
Population)  
TABLE 14.3. 9.4 Summary of All Injection -Related Deaths and Hospitalizations ( Full Exposure 
Safety Population)  
TABLE 1 4.3.9.5 Summary of All Non-Injection Related Deaths and Hospitalizations ( Overall 
Safety Population)  
TABLE 14.3. 9.6 Summary of All Non-Injection Related Deaths and Hospitalizations ( Full 
Exposure Safety Population)  
TABLE 14. 3.10.1 Summary of Columbia -Suicide Severity Ratings  over Time  (Overall Safety 
Population)  
TABLE 14. 3.10.2 Summary of Columbia -Suicide Severity Ratings  over Time  (Full Exposure 
Safety Population)  
TABLE 14. 3.11.1 Summary of Clinical Hematology Data over Time  (Overall Safety Population)  
TABLE 14. 3.11.2 Summary of Clinical Hematology Data over Time  (Full Exposure Safety 
Population)  
TABLE 14. 3.12.1 Shift from Baseline in Laboratory Tests: Hematology ( Overall Safety 
Population)  
TABLE 14. 3.12.2 Shift from Baseline in Laboratory Tests: Hematology ( Full Exposure Safety 
Population)  
TABLE 14. 3.13.1 Summary of Clinical Chemistry Data ( Overall Safety Population)  
TABLE 14. 3.13.2 Summary of Clinical Chemistry Data ( Full Exposure Safety Population)  
TABLE 14. 3.14.1 Shift from Baseline in Laborato ry Tests: Chemistry  (Overall Safety Population)  
TABLE 14. 3.14.2 Shift from Baseline in Laboratory Tests: Chemistry (Full Exposure Safety 
Population)  
TABLE 14. 3.15.1  Summary of Clinical Coagulation Profile Data ( Overall Safety Population)  
TABLE 14. 3.15.2 Summary of Clinical Coagulation Profile Data ( Full Exposure Safety Population)  
TABLE 14. 3.16.1 Shift from Baseline in Laboratory  Tests: Coagulation Profile  (Overall Safety 
Population)  
TABLE 14. 3.16.2 Shift from Baseline in Laboratory Tests: Coagulation Profile  (Full Exposure 
Safety Population)  
TABLE 14. 3.17.1 Summary of Vital Signs over Time  (Overall Safety Population)  
TABLE 14. 3.17.2 Summary of Vital Signs over Time  (Full Exposure Safety Population)  
TABLE 14. 3.18.1 Summary of 12 -Lead ECG Results  (Overall Safety Population)  
TABLE 14. 3.18.2 Summary of 12 -Lead ECG Results  (Full Exposure Safety Population)  
TABLE 14. 3.19.1	
   Summary of 12 -Lead ECG Individual Parameters ( Overall Safety Population)  
TABLE 14. 3.19.2	
   Summary of 12 -Lead ECG Individual Parameter s (Full Exposure Safety 
Population)  
 
List of Listings  
Number  Title  
LISTING 16.2.1.1  Patient Meeting  Inclusion Criteria  
LISTING 16.2.1.2  Patients Meeting Exclusion Criteria  
LISTING 16.2.2	
   Protocol Deviations  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   19	
  of	
  20	
   	
  LISTING 16.2.3	
   Patient Disposition 
LISTING 16.2.4.1 	
   Demographics  
LISTING 16.2.4.2 	
   Psychosocial History  
LISTING 16.2.4.3 	
   Medical History  
LISTING 16.2.4.4  Substance Abuse History and Treatment  
LISTING 16.2.5.1 	
   CAM2038  Injection  
LISTING 16.2.5.2 	
   Injection  Site Examination/ Treatment Compliance  
LISTING 16.2.6.1  COWS, SOWS 
LISTING 16.2.6.2  Need to Use and Desire to Use VAS  
LISTING 16.2.6.3  Urine Toxicology Results for Illicit Opioids  
LISTING 16.2.6.4  Self-Reported Illicit Opioid U se 
LISTING 16.2.6.5  Urine Toxicology Results for Other Drugs of  Abuse  
LISTING 16.2.6.6  Work Productivity and Activity Impairment Questionnaire General Health 
(WPAI -GH) 
LISTING 16.2.6.7  EQ-5D-5L Health Questionnaire  
LISTING 16.2.6.8  Patient Satisfaction Scale  
LISTING 16.2.6.9  Psychosocial Counseling  
LISTING  16.2.7.1  Adverse Events  
LISTING 16.2.7.2  Serious Adverse Events  
LISTING 16.2.7.3  Adverse Events That Lead to Discontinuation from Treatm ent/Study  
LISTING 16.2.7.4  Adverse Events That Have Death as the Outcome  
LISTING 16.2.7.5  Death Report s 
LISTING 16.2.7.6  Prior and Concomitant Medications/Procedures  
LISTING 16.2.8.1  Lab Test Samples  
LISTING 16.2.8.2  Clinical Hematology  
LISTING 16.2.8.3  Clinical Chemistry  
LISTING 16.2.8.4  Clinical Coagulation Profile  
LISTING 16.2.8.5  Urinalysis  
LISTING 16.2.8.6  Serolo gy 
LISTING 16.2.8.7  Pregnancy Test   
LISTING 16.2.8.8  Pregnancies  
LISTING 16.2.9 C-SSRS 
LISTING 16.2. 10 Physical Examination  
LISTING 16.2. 11 Vital Signs  
LISTING 16.2. 12 12-Lead ECG  
LISTING 16.2.13  Patient Visits  
	
  
List of Figures  
FIGURE 14.2.1  Kaplan -Meier Plot of T ime to T reatment Discontinuation (retention in treatment)  
(Efficacy  Population)  
FIGURE 14.2.2  Kaplan -Meier Plot of T ime to S tudy D iscontinuation (retention in study)  
(Efficacy  Population)  
FIGURE 14.2.3  Urine Toxicology Results for Illicit  Opioid Use S upported by Self-Report ed 
Illicit Opioid Use by T ime (Efficacy  Population)  
FIGURE 14.2.4  Urine Toxicology Results for Illicit Opioid Use Without  Self-Reported Illicit 
Opioid Use by T ime (Efficacy  Population)  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   20	
  of	
  20	
   	
  15.2   APPENDIX	
  B 	
  -­‐‑	
  IMPUTATION	
  ALGORITH M	
  FOR	
  PARTIAL	
  AND	
  MI SSING	
  
DATES	
  	
  
This section describes missing date imputation methods.  
 
For Adverse Events  
 
If onset date is completely missing, onset date is set to the date of first study dose date . 
If (year is present and month and day are missing) or  (year and day are present and month is missing):  
•  If year = year of first dosing , then set month and day to month and day of first dosing  
•  If year < year of first dosing , then set month and day to December 31.  
•  If year > year of first dosing , then set month and day to January 1. 
If month and year are present and day is missing:  
•  If year=year of first dosing  and   
•  If month = month of first dosing  then set day to day of first dose  
•  If month < month of first dose then set day to last day of month  
•  If month > month of first dose then set day to first day of month  
•  If year < year of first dosing  then set day to last day of month  
•  If year > year of dosing then set day to first day of month  
 
For all other cases, set onset date to date of first dosing . 
 
For Concomitant Med ications  
 Start Date:   If start date is completely missing and end date is not prior to first dosing , then the medication 
will be classified as concomitant. If start date is completely missing and end date is prior to first dosing , 
then the medication will be classified as prior.  
 
If (year is present and month and day are missing) or (year and day are present and month is missing) then 
set month and day to January 1.   If year and month are present and day is missing then set day to first day 
of month.  
 
End Date:   If end date is completely missing then the medication will be classified as concomitant. 
If (year is present and month and day are missing) or (year and day are present and month is missing) then  
set month and day to December 31.   If year and month are present and day is missing then set day to last 
day of the month.  
 Note : that if both start and end dates are missing then the medication will be classified as concomitant.  